ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1741

Abdominal Fat Mass Assessment in Recent Onset Spondyloarthritis: Data from the DESIR Cohort

Hélène Che1, Adrien Etcheto2, Camille Souffir3, Sami Kolta4, Pascal Richette5, Anna Molto6, Maxime Dougados2, Christian Roux4 and Karine Briot4, 1Cochin Hospital, Paris Descartes University, Paris, France, 2Université Paris René Descartes and Hôpital Cochin, Paris, France, 3Service de rhumatologie, Hopital Cochin, Paris, France, 4Rheumatology B Department, Hôpital Cochin, Paris, France, 5Université Paris Diderot, UFR médicale, Paris, France; APHP Hôpital Lariboisière, Fédération de Rhumatologie and Inserm U1132, Hôpital Lariboisière, Paris, France, 6Hopital Cochin, Paris Descartes University, Paris, France

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: adipose tissue, anti-TNF therapy, dual energy x-ray absorptiometry (DEXA) and spondylarthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Spondylarthropathies and Psoriatic Arthritis - Comorbidities and Treatment Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Studies have shown a strong prevalence of cardiovascular events among patients with spondyloarthritis (SpA). Recent studies indicate that visceral adipose tissue (VAT) is highly associated with insulin resistance and cardiovascular events. Dual energy X-ray absorptiometry (DXA) is a validated technique able to accurately determine cross-sectionally the mass of discret fat deposits.

The objectives of our study were to assess the 2-year changes in abdominal fat mass in patients with early inflammatory back pain suggestive of SpA, in the DESIR cohort and to identify the variables significantly associated with these  changes.

Methods:

Among the 708 patients of the DESIR cohort (inflammatory back pain of less than 3 years duration suggestive of axial SpA), 265 had BMD measurements at baseline and after 2 years of follow-up, and 129 had body composition and abdominal adiposity measurements. Alongside the evaluation of clinical and paraclinical features associated with early SpA and increased cardiovascular risk, DXA was performed to evaluate body composition and abdominal adipose tissue (subcutaneous adipose tissue (SAT) and VAT). We assessed changes in abdominal fat mass (VAT, SAT) over 2 years. Then, we assessed the variables associated with abdominal fat mass changes using linear regressions. Afterwards, we compared the abdominal fat mass changes in patients treated with TNF-blockers or free of TNF-blockers. Finally, we tested the role of inflammation (defined by a CRP >6mg/L or presence of MRI inflammatory signals at the spine or sacro-iliac joint level) in the 2-year abdominal fat mass changes.

Results:

A total of 129 patients of the DESIR cohort (71 men (55.0%), mean age of 33.0 (±8.6) years old) with a mean disease duration of 17.9 (±10.7) months, were included. Their mean body mass index was 23.7 (±3.5) kg/m2 and the prevalence of obesity (BMI>30 kg/m²) was 6.2%. We did not find any significant changes of SAT over 2 years; VAT tended to increase over 2 years from baseline of 7.3% (±28%) (p= 0.054). 2-year VAT changes was significantly associated with the presence of the baseline ASAS criteria fulfillment (p=0.015), hypercholesterolemia at baseline (p=0.007), hypertriglyceridemia at baseline (p=0.0026) and 2-year changes in BMI (p<0.01).

Thirty nine (30.2%) patients received anti-TNF treatment during the 2 years follow-up period. The SAT changes were not significantly different between patients with and without anti-TNF (+2.9%, p=0.323). However, VAT tended to increase from baseline in the anti-TNF group (+5.2%, p=0.053).

Presence or absence of inflammation had no significant impact on 2-year abdominal fat mass changes (p=0.358 for VAT and p=0.508 for SAT).

Conclusion:

To our knowledge, this study is the first one assessing the abdominal adiposity changes in early inflammatory back pain suggestive of SpA. VAT tended to increase over a 2 years follow-up period, especially in patients receiving anti-TNF. Further studies with larger samples are necessary to confirm or not these results and to evaluate their clinical relevance.


Disclosure: H. Che, None; A. Etcheto, None; C. Souffir, None; S. Kolta, None; P. Richette, None; A. Molto, None; M. Dougados, None; C. Roux, None; K. Briot, None.

To cite this abstract in AMA style:

Che H, Etcheto A, Souffir C, Kolta S, Richette P, Molto A, Dougados M, Roux C, Briot K. Abdominal Fat Mass Assessment in Recent Onset Spondyloarthritis: Data from the DESIR Cohort [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/abdominal-fat-mass-assessment-in-recent-onset-spondyloarthritis-data-from-the-desir-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/abdominal-fat-mass-assessment-in-recent-onset-spondyloarthritis-data-from-the-desir-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology